EcoDrugPlus

Nicastrin

Ensembl ID : ENSAMXG00000037882
Gene Symbol: NCSTN
4 Cross references
204 Possible Orthologues:

Nicotinamide Phosphoribosyltransferase

Ensembl ID : ENSAMXG00000037569
Gene Symbol: NAMPT
3 Cross references
219 Possible Orthologues:

Nischarin

Ensembl ID : ENSAMXG00000005024
Gene Symbol: NISCH
3 Cross references
210 Possible Orthologues:

Nitric Oxide Synthase 2

Ensembl ID : ENSAMXG00000011861
Gene Symbol: NOS2
4 Cross references
166 Possible Orthologues:

Nitric Oxide Synthase 2

Ensembl ID : ENSAMXG00000010210
Gene Symbol: NOS2
3 Cross references
166 Possible Orthologues:

Nuclear Factor, Erythroid 2 Like 2

Ensembl ID : ENSAMXG00000007122
Gene Symbol: NFE2L2
3 Cross references
216 Possible Orthologues:

Nuclear Receptor Subfamily 1 Group H Member 4

Ensembl ID : ENSAMXG00000020274
Gene Symbol: NR1H4
3 Cross references
388 Possible Orthologues:

Nuclear Receptor Subfamily 1, Group H, Member 3

Ensembl ID : ENSAMXG00000006277
Gene Symbol: NR1H3
1 Cross references
392 Possible Orthologues:

Nuclear Receptor Subfamily 3 Group C Member 1

Ensembl ID : ENSAMXG00000039789
Gene Symbol: NR3C1
4 Cross references
206 Possible Orthologues:

Nuclear Receptor Subfamily 3 Group C Member 2

Ensembl ID : ENSAMXG00000025608
Gene Symbol: NR3C2
3 Cross references
211 Possible Orthologues:

Nuclear Receptor Subfamily 3, Group C, Member 1 (Glucocorticoid Receptor)

Ensembl ID : ENSAMXG00000011646
Gene Symbol: NR3C1
1 Cross references
207 Possible Orthologues:

Nucleotide Binding Oligomerization Domain Containing 2

Ensembl ID : ENSAMXG00000018642
Gene Symbol: NOD2
3 Cross references
167 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).